Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function

1994 ◽  
pp. 293-299 ◽  
Author(s):  
Eizo Okamoto ◽  
Naoki Yamanaka ◽  
Takeshi Oriyama ◽  
Fumihito Tomoda ◽  
Akio Kyo
Keyword(s):  
Hepatic Function ◽  
Impaired Hepatic Function ◽  
Safe Limits

USE OF VECURONIUM IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION

1985 ◽  
Vol 63 (Supplement) ◽  
pp. A336
Author(s):  
C. Y. LIN ◽  
Y. P. CHOU ◽  
B. D. SCHREIDER
Keyword(s):  
Hepatic Function ◽  
Impaired Hepatic Function

The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function

2008 ◽  
Vol 32 (6) ◽  
pp. 613-621 ◽  
Author(s):  
Milan C. Richir ◽  
Roderick H. Bouwman ◽  
Tom Teerlink ◽  
Michiel P.C. Siroen ◽  
Theo P.G.M. de Vries ◽  
...  
Keyword(s):  
Asymmetric Dimethylarginine ◽  
Hepatic Function ◽  
Impaired Hepatic Function

scholarly journals Effect of Notoginseng Extracts and Its Components on Lipopolysaccharide and Galactosamine Mixture-induced Impaired Hepatic Function in Mice

2012 ◽  
Vol 132 (7) ◽  
pp. 831-836 ◽  
Author(s):  
Ken-ichi Komatsu ◽  
Hiroko Tanaka ◽  
Daisuke Nakagawa ◽  
Keiko Kawashima
Keyword(s):  
Hepatic Function ◽  
Impaired Hepatic Function

scholarly journals Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: A self-perpetuating crosstalk?

2012 ◽  
Vol 1822 (2) ◽  
pp. 176-184 ◽  
Author(s):  
Mariapia Vairetti ◽  
Andrea Ferrigno ◽  
Vittoria Rizzo ◽  
Giulia Ambrosi ◽  
Alberto Bianchi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Hepatic Function ◽  
Rodent Model ◽  
Impaired Hepatic Function

scholarly journals Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S430-S430 ◽  
Author(s):  
Heather Sevinsky ◽  
Mindy Magee ◽  
Peter Ackerman ◽  
Robert Adamczyk ◽  
Jennifer Karkas ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Geometric Mean ◽  
Hepatic Function ◽  
Open Label ◽  
Post Dose ◽  
Viral Attachment ◽  
Linear Mixed Effects ◽  
Active Moiety ◽  
Impaired Hepatic Function ◽  
Hiv 1

Abstract Background Fostemsavir (FTR) is a prodrug of temsavir (TMR), a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T cells. TMR is primarily metabolized via hydrolytic and oxidative pathways; impaired hepatic function may alter TMR pharmacokinetics (PK). Methods AI438053 (NCT02467335) was an open-label, nonrandomized study in healthy subjects (HS) and subjects with hepatic impairment (HI), defined by Child-Pugh (CP) score: mild (CPA), moderate (CPB), or severe (CPC). HS were matched for age, body weight, and sex. Subjects received a single oral dose of FTR 600 mg fasted and serial PK samples for TMR were collected up to 96 hours post-dose. Unbound TMR at 1 and 3 hours post-dose was determined. Total and unbound PK parameters were derived by noncompartmental methods. Geometric mean ratios (GMR) and 90% confidence intervals (CI) for HI vs.. HS were derived using linear mixed-effects models. Subjects were monitored for adverse events (AEs). Results 18 subjects with HI (N = 6/CP group) and 12 HS received FTR and completed the study. Total and unbound TMR exposures increased with increasing HI severity (see Table). Total and unbound TMR CLT/F decreased with increasing HI severity. Mean % protein binding of TMR was 81.0% in HS and 79.9%, 81.9%, and 76.5% in CPA, CPB, and CPC HI, respectively, and was independent of TMR concentration. There were no deaths, serious AEs, or discontinuations during the treatment period. Conclusion TMR exposures increase with increasing severity of HI. The increase in TMR exposures in patients with mild or moderate HI is not expected to alter the safety profile of FTR. The risk/benefit of higher TMR exposures in severe HI is under evaluation. Disclosures H. Sevinsky, ViiV Healthcare: Employee, Salary; M. Magee, GlaxoSmithKline: Employee and Shareholder, Salary; P. Ackerman, ViiV Healthcare/GSK: Employee and Shareholder, Salary and Stock; R. Adamczyk, Bristol-Myers Squibb: Employee, Salary; J. Karkas, Bristol Myers Squibb: Employee and Shareholder, Salary; S. Lubin, Bristol-Myers Squibb: Employee, Salary; P. Ravindran, Bristol-Myers Squibb: Employee, Salary; C. Llamoso, ViiV Healthcare: Employee, Salary; T. Eley, Bristol-Myers Squibb: Former Employee during study conduct, Salary; K. Moore, ViiV Healthcare: Employee, Salary

The pharmacokinetics of lamivudine in patients with impaired hepatic function

1998 ◽  
Vol 54 (4) ◽  
pp. 363-366 ◽  
Author(s):  
M. A. Johnson ◽  
J. Horak ◽  
P. Breuel
Keyword(s):  
Hepatic Function ◽  
Impaired Hepatic Function

Dose Adjustment Should Be Considered for the Administration of Pemafibrate in Patients with Impaired Hepatic Function

2018 ◽  
Vol 32 ◽  
pp. 150
Author(s):  
David Hosford ◽  
Gary Gordon ◽  
Hideki Suganami ◽  
Mitsumasa Nakamura
Keyword(s):  
Dose Adjustment ◽  
Hepatic Function ◽  
Impaired Hepatic Function
Sign in / Sign up

Export Citation Format

Share Document